JUNS
JUPITER NEUROSCIENCES, INC.Company Information
- Company Name
- JUPITER NEUROSCIENCES, INC.
- CIK
- CIK0001679628
- Category
- <br>Emerging growth company
- Ticker: Exchange
- JUNS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- JUNS
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-07-01
- Last sale
- —
- Shares purchased (TTM)
- 12,950
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 1,021,020
- Shares outstanding
- 557,567
- Ownership
- 183.12%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -37.40%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||
| Cash | 2 | 2 | 4 | 1 | 2 | 3 | 4 | 0 | ||||||
| Accounts Receivable Net Current | 0 | - | 0 | - | - | - | - | - | ||||||
| Prepaid Expense Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | ||||||
| Prepaid Expense And Other Assets Current | - | - | - | - | - | - | 0 | - | ||||||
| Inventory Net | 0 | 0 | 0 | - | - | - | - | - | ||||||
| Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 3 | 3 | 5 | 2 | 3 | 4 | 5 | 0 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense Noncurrent | 0 | 1 | 1 | 1 | 1 | 1 | 1 | - | ||||||
| Other Assets Noncurrent | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 4 | 4 | 6 | 3 | 4 | 5 | 6 | 0 | ||||||
Liabilities Current | ||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | ||||||
| Deferred Compensation Liability Current | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 2 | ||||||
| Interest Payable Current | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Contract With Customer Liability Current | - | - | - | 0 | - | - | - | - | ||||||
| Deferred Revenue | - | - | 0 | - | - | - | - | - | ||||||
| Deferred Revenue Current | 0 | - | - | - | - | - | - | - | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Convertible Notes Payable Current | 2 | 5 | 5 | - | - | - | - | 1 | ||||||
| Derivative Liabilities Current | - | - | - | - | - | - | - | 1 | ||||||
| Customer Refund Liability Current | 0 | 0 | - | - | - | - | - | - | ||||||
| Liabilities Current | 4 | 7 | 7 | 3 | 3 | 2 | 2 | 6 | ||||||
| Convertible Long Term Notes Payable | - | - | - | - | - | - | - | 0 | ||||||
| Operating Lease Liability Noncurrent | 0 | - | - | - | - | 0 | 0 | 0 | ||||||
| Liabilities | 4 | 7 | 7 | 3 | 3 | 2 | 2 | 6 | ||||||
Stockholders Equity | ||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 39 | 34 | 33 | 32 | 31 | 31 | 30 | 19 | ||||||
| Retained Earnings Accumulated Deficit | -39 | -37 | -35 | -32 | -30 | -28 | -26 | -24 | ||||||
| Stockholders Equity | -0 | -3 | -2 | 0 | 1 | 3 | 4 | -6 | ||||||
| Debt Instrument Unamortized Discount Current | - | - | - | - | - | - | 0 | 0 | ||||||
| Debt Instrument Unamortized Discount Noncurrent | - | - | - | - | - | - | 0 | 0 | ||||||
| Liabilities And Stockholders Equity | 4 | 4 | 6 | 3 | 4 | 5 | 6 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 125 | 125 | 125 | 125 | 125 | ||||||
| Common Stock Shares Issued | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Shares Outstanding | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialJUPITER NEUROSCIENCES, INC. (JUNS) — SEC Financial Statements & Analysis
JUPITER NEUROSCIENCES, INC. (JUNS) is a pharmaceutical preparations company, incorporated in DE. JUPITER NEUROSCIENCES, INC. trades on Nasdaq as: JUNS. JUPITER NEUROSCIENCES, INC. (JUNS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, JUPITER NEUROSCIENCES, INC. carries a market cap of $8.95M, a P/E ratio of -0.97x, a P/B ratio of -24.45x, a P/S ratio of 208.61x, an enterprise value of $8.96M, and an EV/EBITDA multiple of -0.91x. On profitability, it posts an operating margin of -22872.89%, a net margin of -21445.37%, a Return on Equity (ROE) of -1888.70%, and a Return on Assets (ROA) of -239.36%. Per share, it reports EPS of $-16.50, diluted EPS of $-16.50, free cash flow per share of $-13.00, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 47.87% year-over-year and EPS growth of 17.33% year-over-year. On the balance sheet, it maintains a current ratio of 0.66x, a quick ratio of 0.42x, working capital of $-1.33M, a debt-to-equity ratio of -11.16x, a debt ratio of 1.1, an interest coverage ratio of -35.95x, free cash flow of $-7.25M (TTM), and net debt of $6.59K. Figures sourced from SEC EDGAR.
- Market Cap
- $8.95M
- P/E TTM
- -0.97x
- EPS TTM
- $-16.50
- P/B TTM
- -24.45x
- ROE TTM
- -1888.70%
- ROA TTM
- -239.36%
- Debt To Equity
- -11.16x
- Free Cash Flow TTM
- $-7.25M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is JUPITER NEUROSCIENCES, INC. in?
JUPITER NEUROSCIENCES, INC. (JUNS) operates in the Pharmaceutical Preparations industry.
What exchange does JUNS trade on?
JUPITER NEUROSCIENCES, INC. (JUNS) trades on the Nasdaq.
Where is JUPITER NEUROSCIENCES, INC. incorporated?
JUPITER NEUROSCIENCES, INC. is incorporated in DE.
When was JUPITER NEUROSCIENCES, INC. (JUNS)'s most recent SEC filing?
JUPITER NEUROSCIENCES, INC. (JUNS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is JUNS's market cap?
JUPITER NEUROSCIENCES, INC. (JUNS) has a market capitalization of $8.95M as of 2026-06-30.
What is JUNS's EPS (earnings per share)?
JUPITER NEUROSCIENCES, INC. (JUNS)'s trailing twelve month EPS is $-16.50 as of 2026-06-30.
What is JUNS's ROE (return on equity)?
JUPITER NEUROSCIENCES, INC. (JUNS)'s trailing twelve month Return on Equity (ROE) is -1888.70% as of 2026-06-30.
What is JUNS's ROA (return on assets)?
JUPITER NEUROSCIENCES, INC. (JUNS)'s trailing twelve month Return on Assets (ROA) is -239.36% as of 2026-06-30.
What is JUNS's EV/EBITDA?
JUPITER NEUROSCIENCES, INC. (JUNS)'s trailing twelve month EV/EBITDA is -0.91x as of 2026-06-30.